Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Study ID
NCT06886126
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.

Key Dates

First listed
Mar 20, 2025
Start date
Feb 7, 2025
Status verified
Mar 2025
Primary completion
Sep 23, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HDM1005 dose cohort 1 QW
  • Experimental: HDM1005 dose cohort 2 QW
  • Experimental: HDM1005 dose cohort 3 QW
  • Experimental: HDM1005 dose cohort 4 QW
  • Placebo Comparator: placebo QW

Primary Outcome Measure

Percentage Change From Baseline in Body Weight at Week 22 [ Time Frame: Baseline, Week 22 ]

Central Contacts

Related Studies